Shigeki Yoshiura

Chugai Pharmaceutical

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Immunology Immunology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (9)

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Collaborators (4)

Yoriko Yamashita-Kashima

JAPAN

View details

NATSUMI KAWASAKI

Chugai Pharmaceutical

JAPAN

View details

Narumi Sakaguchi

Chugai Pharmaceutical

JAPAN

View details

Ryohei Katayama

Principal Investigator / Chief

Cancer Institute Hospital of Japanese Foundation for Cancer Research

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Shigeki Yoshiura

Research Interests

Explore related searches

Contact this professor

Articles (9)

Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK‐fusion‐positive lung cancer

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer

Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models

FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes

The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B‐cell lymphoma

Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors

Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies

Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells

Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.

Collaborators (4)

Yoriko Yamashita-Kashima

NATSUMI KAWASAKI

Narumi Sakaguchi

Ryohei Katayama

Make your next move.